• CAS号
  • HIT ID
  • 供应商货号
  • SMILES
  • 化合物库

购物车
0
  2. 结构式搜索
  3. HIT220921692
有库存
HIT220921692
 sdf 文件
结构编辑
类似物检索
HIT220921692
  • HIT ID:HIT220921692
  • Cas No:1041469-97-9
  • 常用名:RKS-262
  • IUPAC:4-{[(6-bromo-4-chloro-2-oxo-2H-chromen-3-yl)methylidene]amino}-3-methyl-1lambda6-thiomorpholine-1,1-dione
    IUPAC:4-{[(6-bromo-4-chloro-2-oxo-2H-chromen-3-yl)methylidene]amino}-3-methyl-1lambda6-thiomorpholine-1,1-dione
  • InChI key:InChIKey=RPUHUUBAOXLODQ-UHFFFAOYSA-N
  • 分子式:C15H14BrClN2O4S
  • 分子量:433.7
  • 氢键供体数 (HBD):
  • 氢键受体数 (HBA):
  • LogP:
  • SMILES:CC1CS(=O)(=O)CCN1N=Cc1c(Cl)c2cc(Br)ccc2oc1=O
    SMILES:CC1CS(=O)(=O)CCN1N=Cc1c(Cl)c2cc(Br)ccc2oc1=O
  • RKS262 is a specific cyclin/CDK inhibitor. RKS262 was identified by structural optimization of Nifurtimox which is currently undergoing phase II clinical trials to treat high-risk neuroblastoma. In a NCI(60) cell-line assay RKS262 exhibited significant cytotoxicity in ovarian cancer cells and a variety of other cell lines exceeding effects of commercial drugs such as cisplatin, 5-FU, cyclophosphamide or sapacitabine. Various leukemia cell-lines were most sensitive (GI(50): ~ 10 nM) while several non-small cell lung cancer cell lines and few cell lines from other tissues were relatively resistant (GI(50) > 1 µM) to RKS262 treatment.
市场产品/服务共显示1个结果
  • 供应商
    TargetMolSC
    规格
    货期
    6-8周
    纯度
    -
    ¥ 10,600.00
    1

寻找合适的化合物库

您无法确定哪种化合物库最适合您的项目？或者您需要定制解决方案？Anymole随时为您提供帮助。
电话：400820-0310
合作：info@screeningcompound.com
技术支持：tech@screeningcompound.com
客服：service@screeningcompound.com
TargetMol | Target Loading
正在加载 ~
常用功能
使用指南化合物搜索在线客服返回顶层